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ABSTRACT: This study assessed the effect of Human Immunodeficiency Virus and Antiretroviral Drugs (ARVs) 
on liver enzyme markers (Aspartate aminotransferase, Alanine aminotransferase and Alkaline phosphatase) and 
CD4 T-cells. A total of Seventy Five (75) individuals were enrolled into the study, which comprised Twenty Five 
(25) HIV negative (control), Twenty Five (25) HIV positive non-treated with ARVs and Twenty Five (25) HIV 
positive treated with antiretroviral drugs (ARVs). Females were found to be the majority of HIV infected patients 
and most patients were at the middle age of 20-39 years. AST and ALT were assessed according to the Reitman 
and Frankel’s (1957) method, while ALP was based on King Armstrong’s (1980) method and CD4 T-cells using a 
method assayed of Cassens et al., (2004). The result show a significant increase (p<0.05) in AST and ALT levels 
of HIV positive non treated group compared to HIV negative group (control). AST and ALT levels of HIV positive 
treated with ARVs is significantly higher in comparison to HIV positive non-treated group. But the ALP activity was 
significantly lower (p<0.05) in HIV positive treated group compared to non-treated group. Infection by HIV 
increases the activities of the three enzymes, which may be due to liver cells apoptosis caused by HIV infection, 
intact immune response to HIV replication which subsequently leads to hepatocellular necrosis and inflammation. 
But at the commencement of antiretroviral therapy the activities of the three afore-mentioned enzymes decreases 
which may be as result of decrease in the negative effect of the virus to the liver enzymes by ARVs. For clinical 
significance, it is necessary to investigate the activities of liver enzymes in HIV positive patients in order to monitor 
the diagnosis and advanced infection of the liver cells by HIV. 
Keywords: Aspartate aminotransferase, Alanine aminotransferase, Alkaline phosphatase, Human 
immunodeficiency virus and antiretroviral drugs.  
INTRODUCTION 
Human immunodeficiency virus belongs to a class of 
retroviruses known as lentiviruses, which are 
characterized by a long period of persistence and 
replication before any onset of disease. HIV virus leads 
to acquired immunodeficiency syndrome (AIDS) a 
condition in which the immune system is compromised, 
leading to life threatening opportunistic infections 
(Coffin et al., 1986). 
In 2005 alone, AIDS claimed an estimated of 2.5 to 3.3 
million lives, of which more than 570,000 were children 
(Greener, 2002). Greener (2002) also reported that 
one-third of the deaths were in sub-saharan Africa. 
Before the introduction of antiretroviral therapy (ART), 
about 15 to 20% of the children born to HIV infected 
mothers became HIV positive due to vertical 
transmission (Thorne et al., 1998). 
Nigeria has a HIV prevalence rate of 5.8% of the adult 
population in 2001, which decreases to 4.4% in 2005 
but still it was ranked as second in Africa and fourth in 
the world with about 3 million people infected (Oladepo 
et al., 2008). 
Antiretroviral drugs are useful in prolonging life and 
postponing complications of AIDS or AIDS related 
complexes (ARC), but do not cure the infection (DHHS, 
2005). Current HAART options are combinations (or 
cocktails) consisting of at least three drugs belonging to 
at least two types/classes of antiretroviral agents.  
The widespread of HIV infection as well as the 
extensive use of these drugs (ARDs) in management of 
HIV infection and speculations of their effects such as 
nausea, vomiting, rash, abdominal pain, skin rashes, 
peripheral neuropathy, pancreatitis, diarrhea, indirect 
hyperbilirubinemia etc, has made it necessary to 
investigate the effect of ARVs to the patients. The 
present study was therefore undertaken to evaluate the 
effect of HIV infection on the liver marker enzymes and 
the risk associated with the use of antiretroviral drugs. 
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MATERIALS AND METHOD 
Research location 
The research was carried out at Specialist Hospital, 
Sokoto. Samples were collected from antiretroviral 
therapy centre (ART) at Specialist Hospital Sokoto.  
 
Study population 
The study population comprised 75 subjects, which 
includes 25 HIV positive non-treated with antiretroviral 
drugs, 25 HIV positive treated, and 25 HIV negative 
(Healthy adult as control) subjects.   
 
Sample collection  
On enrollment, 5mls of blood were aseptically collected 
from each subject using a sterilized syringe into a clean 
dry glass test tube and centrifuged to obtain the serum. 
 
Ethical Clearance and Patients Consent 
The ethical clearance of ethical and research 
committee of Specialist Hospital Sokoto was obtained 
prior to the commencement of the study. Standard 
informed consent form was used to inform the patients 
that give their consent to participate in the study. 
 
Patient’s Treatments Combination 
Patients were treated based on the National 
recommended guideline for the treatment of HIV 
positive patients. The combinations used were as 
follows: 
 
For patients on first line therapy, the combinations 
are: 
i. 2 NRTIs + NNRTIs 
 
For second line ART regimen, the following 
combinations were used:   
ii. 2 NRTIs + A boosted protease inhibitor 
(Indinavir or Ritonavir)    
 
The drugs dosages are: 
iii. NRTIs: Zidovudine – 300mg BD, Lamivudine – 
150mg BD or 300mg OD,  Didanosine – 
<60kg: 250mg OD, >60kg: 400mg, Tenofovir – 
300mg OD. 
iv. NNRTIs: Nevirapine – 200mg OD for 1st 2-
week, 200mg BD thereafter, Efavirenz – 
Nocte: 600mg, >60kg: 800mg. 
v. PIs: Ritonavir – 100mg BD boosting, Indinavir 




i. HIV-positive patients not on treatment and 
those on treatment for one year or less. 
ii. Individuals between the ages of 15-60 years 
old. 
iii. Individuals with no physical sign of metabolic 
syndrome. 
iv. Hepatitis (A, B, or C) negative individuals 
 
Exclusion Criterion 
i. Individuals with physical sign of liver cirrhosis 
or any metabolic syndrome. 
ii. Alcoholic consumption, Cigarette smokers or 
drug abusers. 
iii. Hepatitis A, B or C positive patients 
 
Liver Toxicity Markers 
Aspartate Aminotransferase (AST) and Alanine 
Aminotransferase (ALT)  
AST and ALT was measured according to the method 
of Reitman and Frankel (1957). 
 
Alkaline Phosphatase (ALT) 
Alkaline phosphatase was determined according to the 
method of King Armstrong (1980).  
 
CD4 Cells Count 
The CD4+ T- cells were enumerated using flow 
cytometry (FCM) method (Cassens et al., 2004), using 
Cyflow Counter (Partec, Munster, Germany). 
 
Statistical analysis  
Statistical analysis was performed using Graph pad 
Instat version 3.02 (Graph pad Corp., San Diego, USA). 
The data was analysed using descriptive statistics and 
analysis of variance (Benferroni compare all columns) 
was used to test for the level of significant between 




The effects of antiretroviral drugs on serum AST, ALT, 
and ALP were investigated. The age groups were 
observed to be within the middle age group of 20 to 39 
years, with a significant difference between the age 
group of HIV positive non-treated group and control 
subject.  
The result also shows that majority of HIV infected 
patients are females and constituted 72% and 64%, 
while male constituted 28% and 36% in HIV positive 
non-treated group and treated subjects respectively. 
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All the 25 HIV positive patients non-treated with 
antiretroviral drugs have the serum AST and ALT 
activities significantly higher (p< 0.05) than the control 
group, which is three (3) folds the value of control 
group. A significant difference (p< 0.05) in the activities 
of these two enzymes (AST and ALT) of HIV positive 
treated group was observed compared to the non-
treated group. ALT activity of HIV positive treated group 
is significantly lower (p<0.05) compared to non-treated 
group.  The CD4 T-cells of HIV positive non-treated 
group were significantly lower (p<0.05) than the control 
group, likewise the CD4 T-cells number in HIV positive 
treated with antiretroviral drugs were significantly higher 
(p<0.05) compared to the non-treated group (Table 1).  
 
DISCUSSION 
Highly active antiretroviral therapy (HAART) has 
dramatically improved the prognosis of HIV infection, 
therefore AIDS deaths has been reduced dramatically 
with the initiation of the therapy (Holtzer and Roland, 
1999).  
 
Table 1: Serum Transaminases, and Alkaline Phosphatase of HIV/AIDS Positive non-treated and treated with 
Antiretroviral Drugs.  
 CONTROL HIV+ NON-TREATED HIV+ TREATED 
AGE (YEARS)       38.12±1.65a 29.68±1.41a 30.60±1.84 
GENDER 15M and 10F 7M and 18F 9M and 16F 
AST (U/L)                                         
ALT (U/L) 
ALP (U/L)               
           7.57±0.32a                                                     
           9.23±0.28a                                              
47.58± 2.37 
           44.89±1.13ab                               
           36.08±0.83ab                        
49.39± 1.45a 
9.86±0.21b 
   29.51±0.91b 
34.33± 0.91a 
CD4 T-CELLS (cell/µL) 791.12±33.49a 337.74±59.29ab 516.28±37.51b 
Key: n= Sample size (25/group)      Values are expressed as Mean ± SEM      Values with the same superscript in column are statistically significant (P < 0.05) 
AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, ALP: Alkaline phosphatase, U/L: Unit per litres, M: Male, F: Female 
 
The result of this study revealed that, HIV infected 
patients are at middle age of 20 to 39 years and 
females are the majority of HIV infected patients. This 
finding is inconsistent to report of UNAID, 2010 in which 
they reported that the rate of women living with 
HIV/AIDS rose from 43% in 1999 to 50% in 2010 and in 
Sub-saharan Africa women comprised 59% of the adult 
infected with HIV. A report of study by Babadoko, 
(2005) indicated that in northern Nigeria women 
comprised of 59% of the people living with HIV/AIDS in 
2010. 
 
Many factors were indicated to be attributed to the 
women becoming infected with HIV which may include 
to certain traditional practices such as female genital 
mutilation (FGM) and unfaithful multiple sex partners as 
may occur in polygamous relationships (UNAIDS, 
2003). Moreover poverty and ignorance in addition to 
other socioeconomic conditions may be the driving 
forces increasing the risk of women getting infected 
through increased commercialization of sex (FMOH, 
2010). 
 
The number of people infected with HIV was estimated 
to be 33 million globally, and by increase in the 
accessibility of antiretroviral therapy, the number of 
patients persisting with the HIV increases and also 
increases in the presentation of liver disease (Smith et 
al., 2010). Hepatotoxicity is a major side effect 
described for all antiretroviral drugs (Reisler et al., 
2001, Sulkowski et al., 2000, and Gisolf et al., 2000). 
Hepatotoxicity caused by antiretroviral therapy may be 
associated to number of agents in antiretroviral drug 
classes which include nucleoside reverse transcriptase 
inhibitors (NRTIs), non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) and protease inhibitors (PIs) though 
the severity of hepatotoxicity may range from transient 
elevation of transaminase to hepatic failure and death 
(Nunez, 2010). 
 
Mechanism by which the ART causes liver related 
toxicity particularly NRTIs which causes direct 
mitochondrial toxicity leading to abnormal liver function 
(Murphy et al., 2007), while NNRTIs may cause 
hypersensitivity (Mbougua et al., 2010). Other 
mechanisms include direct cell stress and disturbances 
in lipid or sugar metabolism associated to protease 
inhibitors (Nunez, 2010). 
 
Many studies around the globe showed that HIV 
infection alters the liver function enzymes by either 
direct or indirect mechanism. Megan et al. (2012) 
reported that multiple studies showed that HIV infects a 
wide range of non-hematopoietic cells, including cells in 
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the liver. This may serve as a reason for the elevation 
the liver enzymes observed in the non-treated subjects 
when compared to control group. Our finding was also 
in conformity with the study conducted by Lebovies et 
al. (1988); Cappell (1991) and Lefkowitch (1994) who 
reported that liver enzymes elevation are frequent in 
HIV infected patients. 
 
The finding of our study was contrary to many studies 
that reported antiretroviral drugs are associated with 
liver enzyme elevation in 6-30% of the patients 
(Sulkoski, 2012). Our finding observed that at the 
commencement of ART the activivities of the liver 
enzymes decreases in comparison to the non-treated 
group. It has believed that factors such as alcohol 
consumption, illicit drug or medication abuse, abnormal 
metabolic syndrome and HBV or HCV co-infection are 
among many risk factors for liver enzymes elevation in 
HIV infected patients. All these risk factors for the 
elevation of liver enzymes were among the exclusion 
criterion for this study particularly to the treated 
subjects, this and the duration of treatment used for the 
study (one year) may serve as a reason for the 
decrease in the activities of the liver enzyme noticed in 
the study. 
 
The CD4 T- cells and other component of the immune 
system were among the principal target cells by the HIV 
(Alimonti et al., 2003). Alimonti et al. (2003) also 
reported that antiretroviral drugs were known to inhibit 
the growth and replication of HIV, thereby hindering the 
negative effect of the virus to the CD4 T-cells and other 
cells of the immune system. This may serve as a 
reason for substantial decrease in the CD4 cell count of 
HIV non-treated group compared to the control 
subjects, but at the initiation of ART in the treated group 
the level of CD4 cell increases significantly compared to 
the non-treated group.  
 
CONCLUSION  
In this study, liver enzymes were found to be elevated 
in HIV positive non-treated with antiretroviral drugs 
compared to control subjects, which may be due to the 
fact that studies. For clinical significance, it is important 
to investigate the activities of liver enzymes markers in 
order to monitor the diagnosis and advanced infection 
of the liver cells by HIV. The study was restricted to one 
year duration of ART which may be short to examine 
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